Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 February 2020Website:
http://beamtx.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 25 min agoDividend
Analysts recommendations
Institutional Ownership
BEAM Latest News
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market size is projected to grow to $9.84 billion by 2030.
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.
U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
What type of business is Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
What sector is Beam Therapeutics in?
Beam Therapeutics is in the Healthcare sector
What industry is Beam Therapeutics in?
Beam Therapeutics is in the Biotechnology industry
What country is Beam Therapeutics from?
Beam Therapeutics is headquartered in United States
When did Beam Therapeutics go public?
Beam Therapeutics initial public offering (IPO) was on 06 February 2020
What is Beam Therapeutics website?
https://beamtx.com
Is Beam Therapeutics in the S&P 500?
No, Beam Therapeutics is not included in the S&P 500 index
Is Beam Therapeutics in the NASDAQ 100?
No, Beam Therapeutics is not included in the NASDAQ 100 index
Is Beam Therapeutics in the Dow Jones?
No, Beam Therapeutics is not included in the Dow Jones index
When was Beam Therapeutics the previous earnings report?
No data
When does Beam Therapeutics earnings report?
The next expected earnings date for Beam Therapeutics is 27 February 2025